Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolized Antibiotics and Pembrolizumab in Advanced NSCLC
NCT05777603Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2024
- Primary completion
- Jun 2027
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aztreonam and vancomycin in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Primary endpoint: Dose Limiting Toxicities at 1 year. Started Apr 2024; status: recruiting.
02
Drugs
aztreonamvancomycin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05777603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05777603.